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**Value of the data** •The data provides the information about female to male ratio in the 21-Hydroxylase deficient CAH patients which could be compared to other studies.•The data supports that level of 17-α-OHP in classical CAH patients is higher than non classical CAH patients as mentioned by other researchers and clinicians.•The sequence of the primers mentioned would help other researchers to identify common and novel mutations in CYP21A2 gene.

1. Data {#s0005}
=======

Congenital Adrenal Hyperplasia is an autosomal recessive disorder mainly caused by defects in 21-Hydroxylase gene (CYP21A2) which codes for 21-Hydroxylase enzyme [@bib2]. [Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"} and [Table 1](#t0005){ref-type="table"} indicate ratio of patients (males and females) in classical (SW, SV) and non classical CAH and the associated level of 17-α-OHP which is the substrate of 21-Hydroxylase enzyme. The major disease-causing mutations in CYP21A2 (functional gene) are transferred from CYP21A1P (pseudogene) due to unequal crossing over during meiosis or apparent gene conversion events [@bib3], macro or microconversion events [@bib4]. [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"} elucidate the age of the CAH patients in the classical and nonclassical CAH, the primer sequences which were used for detection of the common mutations, polymorphisms and novel mutations in the CYP21A2 gene. The novel mutations were detected at the frequency of 3%--5% when large cohorts were investigated [@bib5] ([Table 6](#t0030){ref-type="table"}).

2. Experimental design {#s0010}
======================

2.1. Sample collection {#s0015}
----------------------

The patients were categorized into 3 types viz., Salt Wasting (SW), Simple Virilizing (SV) and non classical (NC). CAH patients had varied age groups among the 3 types.

2.2. 17-α-OHP measurement {#s0020}
-------------------------

17-α-OHP was measured in the serum samples of the CAH patients by enzyme-linked immune-sorbent assay (ELISA), based on the principle of competitive binding.

2.3. Identification of common mutations, polymorphisms and novel mutations {#s0025}
--------------------------------------------------------------------------

DNA was isolated by the standard protocols [@bib6]. The common mutations, polymorphisms and the novel mutations were detected the 110 alleles [@bib1]. Various mutations were present at different frequencies in our population [@bib1]. The genotype of the patients and the affected no of alleles were detected in the present study ([Figs. 4](#f0020){ref-type="fig"}, [5](#f0025){ref-type="fig"}). The prevalence of common mutations in 3 sub-types of CAH were also studied in present study ([Fig. 6](#f0030){ref-type="fig"}).
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![Number of patients in each sub-type of CAH.](gr1){#f0005}

![Number of patients in each sub-type of CAH along the male to female ratio in the three sub-types of CAH.](gr2){#f0010}

![Scatter diagram representing the level of 17-α-OHP (ng/ml) in different categories of CAH (classical and non-classical). Levels of 17-α-OHP are higher in classical form of CAH as compared to non-classical form of CAH.](gr3){#f0015}

![Type of genotype and their abundance in Indian CAH patients.](gr4){#f0020}

![Bar diagram representing various mutations identified and the corresponding number of mutated alleles affected with each mutation.](gr5){#f0025}

![Mutations prevailing in different forms of CAH- Salt-Wasting, Simple-Virilizing and Non-Classical respectively in our population.](gr6){#f0030}

###### 

Range of age in CAH patients.

Table 1

  **Category of CAH**   **Minimum age (years)**   **Maximum age (years)**
  --------------------- ------------------------- -------------------------
  Salt wasting          1 month                   19
  Simple virilizing     3.5                       55
  Non classical         17                        24

###### 

Oligonucleotides (primers) used to amplify the CYP21A2 gene including exon-intron boundaries. Column 1 is primer code, column 2 is primer sequence, column 3 is PCR product size (bp), Column 4 is mutation detected and column 5 is annealing temperatures(°C).

Table 2

  **1**       **2**                                                                             **3**   **4**              **5**
  ----------- --------------------------------------------------------------------------------- ------- ------------------ -------
  **P 1**     5′-TGC ATT TCC CTT CCT TGC TTC-3′                                                 952     F1                 63.2
  **P 2**     5′-[GCA GGG AGT AGT CTC CCA AGG]{.ul}- 3′[a](#tbl2fna){ref-type="table-fn"}                                  
  **P 3**     5′-CCT TGG GAG ACT ACT CCC TGC-3′                                                 320     I172N E6 cluster   58.4
  **P 4**     5′-[AGG GGT TCG TAC GGG AGC AAT A]{.ul}-3′[a](#tbl2fna){ref-type="table-fn"}      2070    F2                 64.2
  **P 5**     5′-[CTG AGG TGC CAC TTA TAG CTC]{.ul}-3′[a](#tbl2fna){ref-type="table-fn"}                                   
  **P 6**     5′-AAG CTC CGG AGC CTC CAC CTC G-5′                                               148     P30L               51.5
  **P 7**     5′-[AGA TCA GCC TCT CAC CTT GC]{.ul}-3′[a](#tbl2fna){ref-type="table-fn"}                                    
  **P 8**     5′-TGG GGC ATC CCC AAT CCA GGT CCC-3′                                             156     i2g                62.0
  **P 9**     5′-[ACC AGC TTG TCT GCA GGA GGAT]{.ul}-3′[a](#tbl2fna){ref-type="table-fn"}                                  
  **P 10**    5′-[TCT CCG AAG GTG AGG TAA CA T]{.ul}-3′[a](#tbl2fna){ref-type="table-fn"}       320     I172N              58.4
  **P 11b**   5′-[AGC TGC ATC TCC ACG ATG GA]{.ul}-3′[a](#tbl2fna){ref-type="table-fn"}         696     E6 cluster         60.6
  N allele                                                                                                                 
  **P 11a**   5′-[TCA GCT GCT TCT CCT CGT TGT GG]{.ul}-3′[a](#tbl2fna){ref-type="table-fn"}     696     E6 cluster         60.2
  M allele                                                                                                                 
  **P 12**    5′-GAT CAC ATC GTG GAG ATG CAG CTG-3′                                             781     V281L              71.0
  **P 13**    5′[TGG GCC GTG TGG TGC GGT GGG GCA A]{.ul}-3′[a](#tbl2fna){ref-type="table-fn"}   Q318X                      
  **P 14**    5′CCA GAT TCA GCA GCG ACT G-3′                                                    162     R356W              67.0
  **P 15**    5′-[TGG GGC AAG GCT AAG GGC ACA AC C]{.ul}-3′[a](#tbl2fna){ref-type="table-fn"}                              

underlined primers are antisense primers.

###### 

List of the mutations, PCR product size, the restriction enzyme used and the fragment size obtained after digestion for the detection of the common mutations.

Table 3

  **Mutation**        **PCR product**   **Restriction enzyme**   **Fragments produced after digestion if mutation present**   **Fragments produced after digestion if mutation absent**
  ------------------- ----------------- ------------------------ ------------------------------------------------------------ -----------------------------------------------------------
  P30L                148 bp            Bsh12361                 148 bp                                                       126 bp & 22 bp
  **I172N**           320 bp            Nde 1                    297 bp & 28 bp                                               320 bp
  **V281L**           781 bp            Apa L1                   686 bp & 95 bp                                               375 bp,311 bp & 95 bp
  **i2g**             156 bp            Sau3A1                   133 bp & 23 bp                                               156 bp
  **Q318X**           781 bp            Pst 1                    457 bp,204 bp & 120 bp                                       299 bp,204 bp,158 bp & 120 bp
  **R356W**           163 bp            Eco521                   162 bp                                                       136 bp
  **Gene Deletion**   210 bp            Taq 1                    187 bp                                                       210 bp & 187 bp

###### 

List of the mutations, optimum temperature, time duration required for the detection of the known mutations.

Table 4

  **Mutation**        **Restriction enzyme**   **Temp.**   **Duration of incubation**
  ------------------- ------------------------ ----------- ----------------------------
  P30L                Bsh12361                 37 °C       4 h
  **I172N**           Nde 1                    37 °C       4 h
  **V281L**           Apa L1                   37 °C       4 h
  **i2g**             Sau3A1                   37 °C       2 h
  **Q318X**           Pst 1                    37 °C       4 h
  **R356W**           Eco521                   37 °C       4 h
  **Gene deletion**   Taq 1                    65 °C       4 h

###### 

Mutations or sequence variations, primers used for PCR and restriction enzymes used in detection of normal and mutant alleles.

Table 5

  **Poly-morphim**          **Primer**                                             **PCR product**   **Enzyme**   **Fragment Size (bp)**   
  ------------------------- ------------------------------------------------------ ----------------- ------------ ------------------------ ------------
  **S268T**                 7-F TGCAGGAGAGCCTCGTGGCAGG 7-R ACGCACCTCAGGGTGGTGAAG   212 bp            Nco 1        --                       --
                                                                                                                                             
  **D183E**                 5-F GGAGACAAGATCAAGGTGCCT                              217 bp            --           212                      146 and 66
  5-R CCAGGTCCTCACCCTGAGA                                                                                                                  

###### 

Oligonucleotides primers used for amplification of CYP21A2 gene exons.

Table 6

  **Exons**        **Primer Sequence 5′--3′**   **PCR product (bp)**   **Annealing temperature (°C)**
  ---------------- ---------------------------- ---------------------- --------------------------------
  **Forward 1**    AGCGGATCCCCCGGTGGCCTC        216                    63.0
  **Reverse 1**    CCGTGGCCCAGCCTGCAGATG                               
  **Forward 2**    AGCTCTGAGGACTGATCTTGA        208                    61.8
  **Reverse 2**    CCGTGGCCCAGCCTGCAGATG                               
  **Forward 3**    AGCTCTGAGGACTGATCTTGA        226                    66.4
  **Reverse 3**    AGCAGCAGTTGGAGCCAGGTT                               
  **Forward 4**    GTACGATAGCACCTTCCTGTT        207                    61.8
  **Reverse 4**    GCTGAGTCTCCAACTCTGGTT                               
  **Forward 5**    TTGGGGTTCGCCCTGCCCGTA        217                    68.6
  **Reverse 5**    CAAAGCTTCATCACCCCCTCC                               
  **Forward 6**    AGGAGGGAGTTGACTTGGTGT        193                    63.4
  **Reverse 6**    CTGTTCCCATGTCCACAGTGC                               
  **Forward 7**    TGGGACAGAGGAAATATGCCA        212                    65.5
  **Reverse 7**    CCTTTACZCACCTCTCTCATG                               
  **Forward 8**    GGCTCCTATGTCACCTTGATG        227                    62.1
  **Reverse 8**    CAACCTCCATCCAGTGCCTAG                               
  **Forward 9**    GGTCAGCATCTGGACCCCAGG        212                    66.9
  **Reverse 9**    AGGTTGCAGTTCACTAGGCTG                               
  **Forward 10**   AGGTGCTAACCTGGATAACTG        303                    59.8
  **Reverse 10**   CACATACTGCATGTGAGAGTC                               
